Clinical Trials Logo

Psoriatic Erythroderma clinical trials

View clinical trials related to Psoriatic Erythroderma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05144165 Recruiting - Psoriasis Clinical Trials

Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines

Start date: November 8, 2021
Phase:
Study type: Observational

French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults have been developed by the psoriasis research group of the French Society of Dermatology using literature available until July 2017 (Amatore et al, 2019). Because several systemic treatments have been marketed since then, new guidelines are mandatory. The aim of this study coordinated by the Centre of Evidence of the French Society of Dermatology is to update the available French guidelines using a Delphi method.

NCT ID: NCT04183881 Completed - Psoriatic Arthritis Clinical Trials

A Phase 4 Clinical Study of Brodalumab

Start date: July 4, 2016
Phase: Phase 4
Study type: Interventional

This study [4827-005 (post market)] is designed to evaluate the safety and efficacy of long-term exposure to brodalumab in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic arthritis) who have completed Study 4827-003 (Study 003) and in subjects with pustular psoriasis (generalized) or psoriatic erythroderma who have completed the Study 4827-004 (Study 004). 4827-005 study was conducted as phase 3 clinical trial until July 4th 2016 (approval date in Japan). After that date 4827-005 study was switched to phase 4 study.

NCT ID: NCT02052609 Completed - Psoriatic Arthritis Clinical Trials

A Phase 3 Clinical Study of KHK 4827

Start date: February 2014
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the safety and efficacy of long-term exposure to KHK4827 in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic erythroderma) who have completed Study 4827-003 (Study 003)and in subjects with pustular psoriasis (generalized) or psoriatic erythroderma who have completed the Study 4827-004 (Study 004).

NCT ID: NCT01680159 Completed - Psoriatic Arthritis Clinical Trials

A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis

Start date: July 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of TA-650 at increased dose of 10 mg/kg every 8 weeks in patients with psoriasis in whom effect of the treatment was confirmed after the treatment with Remicade® at 5 mg/kg every 8 weeks but decreased thereafter.